Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma

Neurology. 2006 Jan 10;66(1):127-30. doi: 10.1212/01.wnl.0000188667.66646.1c.

Abstract

Using whole genome expression microarray technology to discover clinically relevant biomarkers for pilocytic astrocytoma (PA), the authors identified matrilin-2 as a unique mRNA overexpressed in PA. Matrilin-2 protein expression was similarly elevated in the majority of sporadic PA, but in only one neurofibromatosis 1-associated PA with an unusually aggressive clinical phenotype. These results suggest that matrilin-2 may be a specific and clinically useful biomarker for discriminating between indolent and clinically aggressive PA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytoma / classification
  • Astrocytoma / diagnosis*
  • Astrocytoma / genetics*
  • Biomarkers, Tumor / genetics*
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / genetics*
  • Cell Transformation, Neoplastic / genetics
  • Child
  • Chromosomes, Human, Pair 8 / genetics
  • DNA Mutational Analysis
  • Extracellular Matrix Proteins / genetics*
  • Extracellular Matrix Proteins / metabolism
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic / genetics
  • Genetic Testing
  • Glycoproteins / genetics*
  • Glycoproteins / metabolism
  • Humans
  • Immunohistochemistry
  • Matrilin Proteins
  • Neurofibromatosis 1 / complications
  • Neurofibromatosis 1 / genetics
  • Oligonucleotide Array Sequence Analysis
  • RNA, Messenger / analysis
  • RNA, Messenger / genetics
  • Up-Regulation / genetics

Substances

  • Biomarkers, Tumor
  • Extracellular Matrix Proteins
  • Glycoproteins
  • MATN2 protein, human
  • Matrilin Proteins
  • RNA, Messenger